Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Significance: Synthetic nanoparticles containing either protein or peptide antigen and the immunosuppressant rapamycin are capable of inducing durable and specific resistance to mounting immune responses toward the antigen. This immunological tolerance operates on lymphocytes even after multiple immunogenic challenges with the antigen and adding enhancers of immune responses (adjuvants). As a result, the animals treated with these tolerogenic nanoparticles (tNPs) show reduced allergic hypersensitivity disorders, protection from disease relapse in a model of multiple sclerosis, and prevention of inhibitory antidrug antibody responses in an animal model of hemophilia A. These results show the potential for nanocarriers to modify the immunoreactivity of a given molecule by providing tolerogenic instructions to the immune system, thereby preventing or reversing pathological and neutralizing immune responses.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Further, tolerogenic rapamycin nanoparticles, but not rapamycin in free form, have been shown to be able to inhibit both cellular and humoral immune response and induce Tregs in mice (40).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [40]
Citations
Cites
Steinman, R. M., Hawiger, D., & Nussenzweig, M. C. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141040 · Cited by 3,122
Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns
Bachmann, M. F., & Jennings, G. T. (2010) · Nature Reviews Immunology · doi:10.1038/nri2868 · Cited by 2,106 · cited 7×
“Thomson and colleagues (26, 27) demonstrated that treating DCs with rapamycin, an inhibitor of the mTOR pathway, induces a tolerogenic DC phenotype capable of inducing Treg differentiation and antigen-specific immune tolerance that is resistant to the proinflammatory cascade triggered by TLR signaling.”
InfluentialmTOR regulates memory CD8 T-cell differentiation
Araki, K., Turner, A. P., Shaffer, V. O., Gangappa, S., Keller, S. A., Bachmann, M. F., Larsen, C. P., & Ahmed, R. (2009) · Nature · doi:10.1038/nature08155 · Cited by 1,575 · cited 1×
“In fact, free rapamycin, administered at an equivalent dose as that used in tNP treatment, showed the opposite trend with respect to inhibition of OVA-specific T-cell expansion and induction of antigen-specific Tregs, perhaps due to the direct effect of free rapamycin on enhancing effector memory T-cell formation (40).”
Goodnow, C. C., Crosbie, J., Adelstein, S., Lavoie, T. B., Smith-Gill, S. J., Brink, R. A., Pritchard-Briscoe, H., Wotherspoon, J. S., Loblay, R. H., Raphael, K., et al. (1988) · Nature · doi:10.1038/334676a0 · Cited by 1,565 · cited 1×
“The transgenic BCR is specific for hen egg lysozyme (HEL), and the presence of this protein results in cell activation of MD4 B cells in vivo and in vitro (33).”
Regulation of Immune Responses by mTOR
Powell, J. D., Pollizzi, K. N., Heikamp, E. B., & Horton, M. R. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075024 · Cited by 836 · cited 2×
“However, conventional therapy with free rapamycin requires chronic systemic administration, resulting in broad immunosuppression due to its direct effect on lymphocytes (28), whereas low doses of rapamycin may paradoxically augment effector T-cell memory (29).”
Synthesis and characterization of PLGA nanoparticles
Astete, C. E., & Sabliov, C. M. (2006) · Journal of Biomaterials Science, Polymer Edition · doi:10.1163/156856206775997322 · Cited by 776 · cited 1×
“tNPs containing both antigen and rapamycin were prepared using a water-in-oil-in-water double emulsion solvent evaporation method (44, 45).”
Engineering synthetic vaccines using cues from natural immunity
Irvine, D. J., Swartz, M. A., & Szeto, G. L. (2013) · Nature Materials · doi:10.1038/nmat3775 · Cited by 594 · cited 8×
“Thomson and colleagues (26, 27) demonstrated that treating DCs with rapamycin, an inhibitor of the mTOR pathway, induces a tolerogenic DC phenotype capable of inducing Treg differentiation and antigen-specific immune tolerance that is resistant to the proinflammatory cascade triggered by TLR signaling.”
InfluentialTargeted disruption of the mouse factor VIII gene produces a model of haemophilia A
Bi, L., Lawler, A. M., Antonarakis, S. E., High, K. A., Gearhart, J. D., & Kazazian, H. H. (1995) · Nature Genetics · doi:10.1038/ng0595-119 · Cited by 593 · cited 1×
“tNPs containing both antigen and rapamycin were prepared using a water-in-oil-in-water double emulsion solvent evaporation method (44, 45).”
How Tolerogenic Dendritic Cells Induce Regulatory T Cells
Maldonado, R. A., & von Andrian, U. H. (2010) · Advances in Immunology · doi:10.1016/b978-0-12-380995-7.00004-5 · Cited by 541 · cited 1×
“The codelivery of antigen and rapamycin provide an instruction set that could allow for the conditioning of tolerogenic DCs capable of inducing CD4+ Treg (22, 23).”
Self-citationUpdated assessment of the prevalence, spectrum and case definition of autoimmune disease
Hayter, S. M., & Cook, M. C. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.02.001 · Cited by 464 · cited 1×
“Clin Rev Allergy Immunol 37(2):114–124.”
Cited by
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Targeting Strategies for Tissue-Specific Drug Delivery
Zhao, Z., Ukidve, A., Kim, J., & Mitragotri, S. (2020) · Cell · doi:10.1016/j.cell.2020.02.001 · Cited by 1,099
A STING-activating nanovaccine for cancer immunotherapy
Luo, M., Wang, H., Wang, Z., Cai, H., Lu, Z., Li, Y., Du, M., Huang, G., Wang, C., Chen, X., et al. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.52 · Cited by 900
Advances in Biomaterials for Drug Delivery
Fenton, O. S., Olafson, K. N., Pillai, P. S., Mitchell, M. J., & Langer, R. (2018) · Advanced Materials · doi:10.1002/adma.201705328 · Cited by 855
Self-citationSynthetic Nanoparticles for Vaccines and Immunotherapy
Irvine, D. J., Hanson, M. C., Rakhra, K., & Tokatlian, T. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00109 · Cited by 763
From Sewer to Saviour—Targeting the Lymphatic System to Promote Drug Exposure and Activity
Trevaskis, N. L., Kaminskas, L. M., & Porter, C. J. H. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4608 · Cited by 654
Therapeutic targeting of trained immunity
Mulder, W. J. M., Ochando, J., Joosten, L. A. B., Fayad, Z. A., & Netea, M. G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0025-4 · Cited by 443
Nanotechnology for protein delivery: Overview and perspectives
Yu, M., Wu, J., Shi, J., & Farokhzad, O. C. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.012 · Cited by 410
“Recently, Maldonado and colleagues reported an antigen-specific tolerogenic technology that controls both T-cell- and B-cell-mediated immunity using biodegradable nanoparticles [90].”
BackgroundSelf-citationVilla, C. H., Anselmo, A. C., Mitragotri, S., & Muzykantov, V. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.02.007 · Cited by 397
“RBC and platelet internal loading [44,50] and particle-based delivery systems [51] have demonstrated promise in overcoming these limitations, but the efficacy of the RBC surface loading for induction of tolerance is remarkable given its relative simplicity, and opens the possibility of RBCs as carriers of virtually al…”
BackgroundNanotechnology for COVID-19: Therapeutics and Vaccine Research
Chauhan, G., Madou, M. J., Kalra, S., Chopra, V., Ghosh, D., & Martinez-Chapa, S. O. (2020) · ACS Nano · doi:10.1021/acsnano.0c04006 · Cited by 385
Beyond antigens and adjuvants: formulating future vaccines
Moyer, T. J., Zmolek, A. C., & Irvine, D. J. (2016) · Journal of Clinical Investigation · doi:10.1172/jci81083 · Cited by 374
“However, PLGA particle formulations of danger signals or tolerogenic compounds may be an effective strategy to influence adjuvant kinetics in vaccination, and such approaches are under development in preclinical models (48, 62, 121).”
BackgroundFeng, X., Xu, W., Li, Z., Song, W., Ding, J., & Chen, X. (2019) · Advanced Science · doi:10.1002/advs.201900101 · Cited by 363
Tordesillas, L., Berin, M. C., & Sampson, H. A. (2017) · Immunity · doi:10.1016/j.immuni.2017.07.004 · Cited by 337
Song, Y., Li, J., & Wu, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01952-8 · Cited by 259
Inducing immune tolerance with dendritic cell-targeting nanomedicines
Cifuentes-Rius, A., Desai, A., Yuen, D., Johnston, A. P. R., & Voelcker, N. H. (2021) · Nature Nanotechnology · doi:10.1038/s41565-020-00810-2 · Cited by 297
Programming gene and engineered-cell therapies with synthetic biology
Kitada, T., DiAndreth, B., Teague, B., & Weiss, R. (2018) · Science · doi:10.1126/science.aad1067 · Cited by 281
“coadministered therapeutic biologics and poly(lactic-coglycolic acid)–encapsulated rapamycin nanoparticles to mice and nonhuman primates to induce immunological tolerance toward the biologics andprevented antidrug immune responses (97, 98).”
BackgroundMeliani, A., Boisgerault, F., Hardet, R., Marmier, S., Collaud, F., Ronzitti, G., Leborgne, C., Costa Verdera, H., Simon Sola, M., Charles, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06621-3 · Cited by 265
Self-citationZhang, S., Langer, R., & Traverso, G. (2017) · Nano Today · doi:10.1016/j.nantod.2017.08.006 · Cited by 250
Self-citationNanomedicines for renal disease: current status and future applications
Kamaly, N., He, J. C., Ausiello, D. A., & Farokhzad, O. C. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.156 · Cited by 250
Self-citationPharmapolymers in the 21st century: Synthetic polymers in drug delivery applications
Englert, C., Brendel, J. C., Majdanski, T. C., Yildirim, T., Schubert, S., Gottschaldt, M., Windhab, N., & Schubert, U. S. (2018) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2018.07.005 · Cited by 247
Multiple sclerosis: Neuroimmune crosstalk and therapeutic targeting
Charabati, M., Wheeler, M. A., Weiner, H. L., & Quintana, F. J. (2023) · Cell · doi:10.1016/j.cell.2023.03.008 · Cited by 222
Tolerance through Education: How Tolerogenic Dendritic Cells Shape Immunity
Domogalla, M. P., Rostan, P. V., Raker, V. K., & Steinbrink, K. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01764 · Cited by 228
“For instance, polymeric synthetic nanoparticles that target DCs have been used to induce OVA-specific tolerance by delivery of rapamycin (99).”
BackgroundHarnessing nanoparticles for immune modulation
Getts, D. R., Shea, L. D., Miller, S. D., & King, N. J. C. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.05.007 · Cited by 233
Antigen-specific therapeutic approaches for autoimmunity
Serra, P., & Santamaria, P. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0015-4 · Cited by 228
Sharma, N., Bhatia, S., Chunduri, V., Kaur, S., Sharma, S., Kapoor, P., Kumari, A., & Garg, M. (2020) · Frontiers in Nutrition · doi:10.3389/fnut.2020.00006 · Cited by 198
Overcoming innate immune barriers that impede AAV gene therapy vectors
Muhuri, M., Maeda, Y., Ma, H., Ram, S., Fitzgerald, K. A., Tai, P. W. L., & Gao, G. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143780 · Cited by 212
Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles
Kishimoto, T. K., Ferrari, J. D., LaMothe, R. A., Kolte, P. N., Griset, A. P., O'Neil, C., Chan, V., Browning, E., Chalishazar, A., Kuhlman, W., et al. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2016.135 · Cited by 201
Self-citationShields, C. W., Wang, L. L., Evans, M. A., & Mitragotri, S. (2020) · Advanced Materials · doi:10.1002/adma.201901633 · Cited by 193
Improving Vaccine and Immunotherapy Design Using Biomaterials
Bookstaver, M. L., Tsai, S. J., Bromberg, J. S., & Jewell, C. M. (2018) · Trends in Immunology · doi:10.1016/j.it.2017.10.002 · Cited by 183
Targeted modulation of immune cells and tissues using engineered biomaterials
Yousefpour, P., Ni, K., & Irvine, D. J. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-022-00016-2 · Cited by 164
Nanoparticles for the Induction of Antigen-Specific Immunological Tolerance
Kishimoto, T. K., & Maldonado, R. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00230 · Cited by 167
“These tNPs were selectively taken up by APCs in lymphoid organs (66) and demonstrated efficacy when coadministered with antigen by i.”
BackgroundInfluentialSelf-citationNatural and Induced Tolerogenic Dendritic Cells
Iberg, C. A., & Hawiger, D. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1901121 · Cited by 159
Therapeutic induction of antigen-specific immune tolerance
Kenison, J. E., Stevens, N. A., & Quintana, F. J. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00970-x · Cited by 179
“responses 102–104, 202 , One of the first attempts to combine autoantigens and immuno-modulatory drugs used liposomes to co-deliver an antigen and an NF-κB inhibitor, ameliorating experimental arthritis in a FOXP3 + T reg cell-dependent manner 203 .”
Designing inorganic nanomaterials for vaccines and immunotherapies
Hess, K. L., Medintz, I. L., & Jewell, C. M. (2019) · Nano Today · doi:10.1016/j.nantod.2019.04.005 · Cited by 155
Multiple sclerosis: molecular pathogenesis and therapeutic intervention
Boutitah-Benyaich, I., Eixarch, H., Villacieros‐Álvarez, J., Hervera, A., Cobo‐Calvo, Á., Montalbán, X., & Espejo, C. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02415-4 · Cited by 161
Ferritin-based drug delivery systems: Hybrid nanocarriers for vascular immunotargeting
Khoshnejad, M., Parhiz, H., Shuvaev, V. V., Dmochowski, I. J., & Muzykantov, V. R. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.02.042 · Cited by 160
Modulating the immune system through nanotechnology
Dacoba, T. G., Ana, O., Torres, D., Crecente‐Campo, J., & Alonso, M. J. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.09.007 · Cited by 160
Cellular and Molecular Mechanisms of Autoimmune Hepatitis
Webb, G. J., Hirschfield, G. M., Krawitt, E. L., & Gershwin, M. E. (2018) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043534 · Cited by 142
Tostanoski, L. H., Chiu, Y.-C., Gammon, J. M., Simon, T., Andorko, J. I., Bromberg, J. S., & Jewell, C. M. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.08.033 · Cited by 147
“One further rationale for co-delivery of tolerogenic signals (e.g., Rapa) with selfantigen is to mitigate the risk of exacerbating disease with a therapy containing disease-relevant antigen during active autoimmunity (Maldonado et al., 2015).”
InfluentialReconfigurable Swarms of Ferromagnetic Colloids for Enhanced Local Hyperthermia
Wang, B., Chan, K. F., Yu, J., Wang, Q., Yang, L., Chiu, P. W. Y., & Zhang, L. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201705701 · Cited by 151
Cano, A., Sánchez-López, E., Ettcheto, M., López-Machado, A., Espina, M., Souto, E. B., Galindo, R., Camins, A., García, M. L., & Turowski, P. (2020) · Nanomedicine · doi:10.2217/nnm-2019-0443 · Cited by 144
Sushnitha, M., Evangelopoulos, M., Tasciotti, E., & Taraballi, F. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00627 · Cited by 147
“Upon exposure of these tumor antigens, immature DCs process these antigens and present these peptides to T cells (Gardner and Ruffell, 2016).”
BackgroundInfluentialTolerance in the Age of Immunotherapy
Bluestone, J. A., & Anderson, M. S. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1911109 · Cited by 150
Howard, G. P., Verma, G., Ke, X., Thayer, W. M., Hamerly, T., Baxter, V. K., Lee, J. E., Dinglasan, R. R., & Mao, H. (2019) · Nano Research · doi:10.1007/s12274-019-2301-3 · Cited by 133
Engineering immunomodulatory biomaterials for type 1 diabetes
Stabler, C. L., Li, Y., Stewart, J. M., & Keselowsky, B. G. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0112-5 · Cited by 125
Nanoparticle formulated vaccines: opportunities and challenges
Lung, P., Yang, J., & Li, Q. (2020) · Nanoscale · doi:10.1039/c9nr08958f · Cited by 134
McHugh, M. D., Park, J. Y., Uhrich, R., Gao, W., Horwitz, D. A., & Fahmy, T. M. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.04.003 · Cited by 129
Liu, Q., Wang, X., Liu, X., Kumar, S., Gochman, G. E., Ji, Y. C., Liao, Y., Chang, C. H., Situ, W., Lu, J., et al. (2019) · ACS Nano · doi:10.1021/acsnano.9b01444 · Cited by 130
Cappellano, G., Comi, C., Chiocchetti, A., & Dianzani, U. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20010204 · Cited by 126
“loaded with the immunodominant 139–151 epitope of PLP (PLP139–151) in SJL mice together with rapamycin [90], used as inverse adjuvant, and administrated them i.”
MethodEvaluating and mitigating the immunogenicity of therapeutic proteins
Sauna, Z. E., Lagassé, D., Pedras-Vasconcelos, J., Golding, B., & Rosenberg, A. S. (2018) · Trends in biotechnology · doi:10.1016/j.tibtech.2018.05.008 · Cited by 118
In vivo reprogramming of immune cells: Technologies for induction of antigen-specific tolerance
Pearson, R. M., Casey, L. M., Hughes, K. R., Miller, S. D., & Shea, L. D. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.04.005 · Cited by 121
Tolerogenic Ag-PLG nanoparticles induce tregs to suppress activated diabetogenic CD4 and CD8 T cells
Prasad, S., Neef, T., Xu, D., Podojil, J. R., Getts, D. R., Shea, L. D., & Miller, S. D. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.12.010 · Cited by 120
“Antigen-specific approaches include delivery of antigen on/in nanoparticles targeting MARCO or scavenger receptor class F member 1 (SCARF1) scavenger receptors [42,43], antigen loaded particles containing rapamycin [41,44,45] or arylhydrocarbon receptor agonists ligands [46,47] to condition tolerogenic antigen present…”
BackgroundPiperigkou, Z., Καραμάνου, Κ., Engin, A. B., Gialeli, C., Docea, A. O., Vynios, D. H., Pavão, M. S. G., Golokhvast, K. S., Shtilman, M. I., Argiris, A. E., et al. (2016) · Food and Chemical Toxicology · doi:10.1016/j.fct.2016.03.003 · Cited by 118
“Treatment with tolerogenic NPs results in inhibition of CD4þ and CD8þ T-cell activation, increase in regulatory cells, and durable B-cell tolerance resistant to multiple immunogenic challenges (Maldonado et al., 2015).”
Exploiting lymphatic vessels for immunomodulation: Rationale, opportunities, and challenges
Maisel, K., Sasso, M. S., Potin, L., & Swartz, M. A. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.07.005 · Cited by 113
LaMothe, R. A., Kolte, P. N., Vo, T., Ferrari, J. D., Gelsinger, T. C., Wong, J., Chan, V. T., Ahmed, S., Srinivasan, A., Deitemeyer, P., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00281 · Cited by 109
“nanoparticles (nPs) Manufacture of NPs has been previously described (18).”
BackgroundMethodInfluentialSelf-citationNanoparticles for Immune Stimulation Against Infection, Cancer, and Autoimmunity
Singha, S., Shao, K., Ellestad, K. K., Yang, Y., & Santamaría, P. (2018) · ACS Nano · doi:10.1021/acsnano.8b05950 · Cited by 118
Tolerogenic nanoparticles suppress central nervous system inflammation
Kenison, J. E., Jhaveri, A. M., Li, Z., Khadse, N., Tjon, E. C., Tezza, S., Nowakowska, D., Plasencia, A., Stanton, V. P., Sherr, D. H., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2016451117 · Cited by 111
“Indeed, nanoparticles have been used to target specific cell types, codeliver multiple therapeutic agents to the same cell, facilitate the transport of drugs across biological barriers, and protect encapsulated therapeutic agents from in vivo degradation and clearance (21, 22, 58, 60, 61).”
BackgroundHow and why patterns of sexual dimorphism in human faces vary across the world
Kleisner, K., Tureček, P., Roberts, S. C., Havlíček, J., Valentová, J. V., Akoko, R. M., Leongómez, J. D., Apostol, S., Varella, M. A. C., & Sarıbay, S. A. (2021) · Scientific Reports · doi:10.1038/s41598-021-85402-3 · Cited by 114
Drug nanocarriers to treat autoimmunity and chronic inflammatory diseases
Prosperi, D., Colombo, M., Zanoni, I., & Granucci, F. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.08.010 · Cited by 106
De novo design of functional zwitterionic biomimetic material for immunomodulation
Li, B., Yuan, Z., Jain, P. R., Hung, H., He, Y., Lin, X., McMullen, P., & Jiang, S. (2020) · Science Advances · doi:10.1126/sciadv.aba0754 · Cited by 107
Emerging Therapeutics for Immune Tolerance: Tolerogenic Vaccines, T cell Therapy, and IL-2 Therapy
Moorman, C. D., Sohn, S. J., & Phee, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.657768 · Cited by 115
An antigen-encapsulating nanoparticle platform for TH1/17 immune tolerance therapy
McCarthy, D. P., Yap, J. W. T., Harp, C. T., Song, W. K., Chen, J., Pearson, R. M., Miller, S. D., & Shea, L. D. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2016.09.007 · Cited by 103
Tolerogenic Dendritic Cell-Based Approaches in Autoimmunity
Passeri, L., Fortunato, M., Bassi, V., & Gregori, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168415 · Cited by 105
Smarr, C. B., Yap, W. T., Neef, T., Pearson, R. M., Hunter, Z. N., Ifergan, I., Getts, D. R., Bryce, P. J., Shea, L. D., & Miller, S. D. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1505782113 · Cited by 105
“administration of PLG(Ag) containing rapamycin induces tolerance in models of autoimmunity and allergic hypersensitivity (25).”
BackgroundLiu, Y., Chen, X., Yang, P., Qiao, Z., & Wang, H. (2019) · Biomacromolecules · doi:10.1021/acs.biomac.8b01510 · Cited by 100
Nanoparticle-Based Modulation of the Immune System
Fang, R. H., & Zhang, L. (2016) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-080615-034446 · Cited by 109
Multicomponent Injectable Hydrogels for Antigen‐Specific Tolerogenic Immune Modulation
Verbeke, C. S., Gordo, S., Schubert, D. A., Lewin, S. A., Desai, R. M., Dobbins, J., Wucherpfennig, K. W., & Mooney, D. J. (2017) · Advanced Healthcare Materials · doi:10.1002/adhm.201600773 · Cited by 101
Pearson, R. M., Casey, L. M., Hughes, K. R., Wang, L. Z., North, M. G., Getts, D. R., Miller, S. D., & Shea, L. D. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.04.015 · Cited by 103
Modulation of immune responses in lentiviral vector-mediated gene transfer
Annoni, A., Gregori, S., Naldini, L., & Cantore, A. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.04.012 · Cited by 99
Polymeric micro- and nanoparticles for immune modulation
Ben‐Akiva, E., Est-Witte, S. E., Meyer, R. A., Rhodes, K. R., & Green, J. J. (2019) · Biomaterials Science · doi:10.1039/c8bm01285g · Cited by 102
Nanoparticle impact on innate immune cell pattern-recognition receptors and inflammasomes activation
Silva, A. L., Peres, C., Conniot, J., Matos, A. I., Moura, L., Carreira, B., Sainz, V., Scomparin, A., Satchi-Fainaro, R., Préat, V., et al. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.09.003 · Cited by 95
Harnessing the biology of regulatory T cells to treat disease
Wardell, C. M., Boardman, D. A., & Levings, M. K. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01089-x · Cited by 100
“Moreover, nanoparticles can be loaded with T reg -promoting substances such as rapamycin 128 , TGFβ 129 or F5111 immunocytokine 130 .”
Nanoparticle-based autoimmune disease therapy
Serra, P., & Santamaría, P. (2015) · Clinical Immunology · doi:10.1016/j.clim.2015.02.003 · Cited by 95
Immune Tolerance for Autoimmune Disease and Cell Transplantation
Luo, X., Miller, S. D., & Shea, L. D. (2016) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-110315-020137 · Cited by 102
“(48) were less efficient at tolerance induction, recent research with smaller particles loaded with rapamycin were employed to promote tolerance via intravenous delivery (49).”
BackgroundKuo, R., Saito, E., Miller, S. D., & Shea, L. D. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.032 · Cited by 95
The rise of food allergy: Environmental factors and emerging treatments
Benedé, S., Blázquez, A.-B., Chiang, D. S., Tordesillas, L., & Berin, M. C. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.04.012 · Cited by 97
“(Yamaki and Yoshino, 2012), and recently it was shown that selective delivery of antigen plus rapamycinwithin nanoparticles could effectively prevent, and partially treat, food-induced anaphylaxis through induction of regulatory mechanisms (Maldonado et al., 2015).”
BackgroundLiu, Q., Wang, X., Liu, X., Liao, Y., Chang, C. H., Mei, K., Jiang, J., Tseng, S., Gochman, G. E., Huang, M., et al. (2020) · ACS Nano · doi:10.1021/acsnano.0c09206 · Cited by 88
Recent advances in the use of nanoparticles for allergen‐specific immunotherapy
Pohlit, H., Bellinghausen, I., Frey, H., & Saloga, J. (2017) · Allergy · doi:10.1111/all.13199 · Cited by 92
“Th2 to Th1 responses and an upregulation of regulatory T cells leading to decreased lung inflammation and mucus secretion, reduced numbers of total cells and eosinophils in bronchoalveolar lavage (BAL) fluid as well as decreased anaphylaxis.(20-26) In either cases, co-encapsulation of Th1 activator CpG-ODN or the immu…”
BackgroundAntigen-specific immunotherapies in rheumatic diseases
Pozsgay, J., Szekanecz, Z., & Sármay, G. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.107 · Cited by 90
Lewis, J. S., Stewart, J. M., Marshall, G. P., Carstens, M. R., Zhang, Y., Dolgova, N. V., Xia, C., Brusko, T. M., Wasserfall, C. H., Clare-Salzler, M. J., et al. (2019) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.9b00332 · Cited by 89
Small-molecule-based regulation of RNA-delivered circuits in mammalian cells
Wagner, T. E., Becraft, J. R., Bodner, K., Teague, B. P., Zhang, X., Woo, A. R. E., Porter, E. B., Alburquerque, B., Dobosh, B. S., Andries, O., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0146-9 · Cited by 85
Tolerogenic dendritic cells in organ transplantation
Ochando, J., Ordikhani, F., Jordan, S., Boros, P., & Thomson, A. W. (2019) · Transplant International · doi:10.1111/tri.13504 · Cited by 91
“PLGA-NPs Either protein or peptide Ags and rapamycin In vivo Inhibition of Ag-specific CD4 and CD8 T cells and B-cell activation while inducing Ag-specific Tregs and Bregs [64]”
BackgroundInfluentialCho, J. J., Stewart, J. M., Drashansky, T. T., Brusko, M., Zuniga, A. N., Lorentsen, K. J., Keselowsky, B. G., & Avram, D. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.07.029 · Cited by 86
Casey, L. M., Pearson, R. M., Hughes, K. R., Liu, J. M.-H., Rose, J. A., North, M. G., Wang, L. Z., Lei, M., Miller, S. D., & Shea, L. D. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00624 · Cited by 84
Thompson, E. A., Ols, S., Miura, K., Rausch, K. M., Narum, D. L., Spångberg, M., Juraska, M., Wille-Reece, U., Weiner, A. J., Howard, R. F., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120692 · Cited by 80
Self-citationNanomodulation of Macrophages in Multiple Sclerosis
Nally, F. K., Santi, C. D., & McCoy, C. E. (2019) · Cells · doi:10.3390/cells8060543 · Cited by 83
“Interestingly, coupling the myelin antigen with immunomodulatory agents like dexamethasone [175], IL-10 [174], 2-(1′Hindole-3′-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE) [172], or rapamycin [168,181] has shown efficacy in the EAE model.”
BackgroundInfluentialDesign of Polyelectrolyte Multilayers to Promote Immunological Tolerance
Tostanoski, L. H., Chiu, Y.-C., Andorko, J. I., Guo, M., Zeng, X., Zhang, P., Royal, W., & Jewell, C. M. (2016) · ACS Nano · doi:10.1021/acsnano.6b04001 · Cited by 80
Engineering Immune Tolerance with Biomaterials
Gammon, J. M., & Jewell, C. M. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201801419 · Cited by 77
Shaw, J. R., Caprio, N., Truong, N., Weldemariam, M. M., Tran, A. Q., Pilli, N. R., Pandey, S., Jones, J. W., Kane, M. A., & Pearson, R. M. (2025) · Nature Communications · doi:10.1038/s41467-025-56210-4 · Cited by 84
Tolerating Factor VIII: Recent Progress
Lacroix‐Desmazes, S., Voorberg, J., Lillicrap, D., Scott, D. W., & Pratt, K. P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02991 · Cited by 86
“utilized tNPs containing rapamycin given together with repeated doses of FVIII (177).”
MethodSelf-citationBenne, N., Leboux, R., Glandrup, M., van Duijn, J., Vigario, F. L., Neustrup, M. A., Romeijn, S. G., Galli, F., Kuiper, J., Jiskoot, W., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.12.003 · Cited by 79
“Many of these tolerogenic nanoparticles co-encapsulate antigens with ligands to enhance tolerance or inhibit effector responses, such as CD22 [7] or rapamycin [8,9], respectively.”
BackgroundNanoparticles and direct immunosuppression
Ngobili, T. A., & Daniele, M. A.-A. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370216650053 · Cited by 79
Promising Nanotechnology Approaches in Treatment of Autoimmune Diseases of Central Nervous System
Chountoulesi, M., & Demetzos, C. (2020) · Brain Sciences · doi:10.3390/brainsci10060338 · Cited by 79
“[95] developed synthetic, biodegradable PLGA nanoparticles loaded with the immunodominant 139–151 epitope of myelin proteolipid protein (PLP139–151) together with the tolerogenic immunomodulator rapamycin, used as an inverse adjuvant, in order to induce durable and antigen-specific immune tolerance, even in the presen…”
BackgroundImmunomodulation for Tissue Repair and Regeneration
Moon, S., Hong, J., Go, S., & Kim, B. (2023) · Tissue Engineering and Regenerative Medicine · doi:10.1007/s13770-023-00525-0 · Cited by 77
Strategies to Reduce the Immunogenicity of Recombinant Immunotoxins
Mazor, R., King, E. M., & Pastan, I. H. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.04.016 · Cited by 77
“Although the exact mechanism of preventing the immune response is not clear, the injection of the SVP-R results in its accumulation in the liver, spleen, and draining lymph nodes.(62) Nanoparticles are preferentially phagocytosed by antigen-presenting cells because of their size, charge, and shape.”
BackgroundNorthrup, L., Christopher, M. A., Sullivan, B. P., & Berkland, C. J. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.020 · Cited by 73
Li, P. Y., Bearoff, F. M., Zhu, P., Fan, Z., Zhu, Y., Fan, M., Cort, L., Kambayashi, T., Blankenhorn, E. P., & Cheng, H. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.01.013 · Cited by 74
“For instance, rapamycin and TGF-ß have demonstrated the ability to enhance the tolerogenic effect of nanoparticles [16, 32, 48].”
BackgroundSaito, E., Kuo, R., Kramer, K. R., Gohel, N., Giles, D. A., Moore, B. B., Miller, S. D., & Shea, L. D. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119432 · Cited by 74
“The biodistribution for all particles agrees with previous reports that particles of this diameter accumulate mostly in the liver, lung and spleen [19,22,72].”
BackgroundPandya, A. D., Øverbye, A., Sahariah, P., Gaware, V. S., Høgset, H., Másson, M., Høgset, A., Mælandsmo, G. M., Skotland, T., Sandvig, K., et al. (2020) · Biomacromolecules · doi:10.1021/acs.biomac.0c00061 · Cited by 72
Horwitz, D. A., Bickerton, S., Koss, M. N., Fahmy, T. M., & Cava, A. L. (2018) · Arthritis & Rheumatology · doi:10.1002/art.40773 · Cited by 70
“PLGA NPs encapsulating tolerogenic peptides or peptides and rapamycin that targeted APCs prevented or reversed disease in animal models of autoimmune diabetes and multiple sclerosis through TGFβdependent induction of Treg cells (33,34).”
Background
Metadata
- Authors
- Maldonado, R. A., LaMothe, R. A., Ferrari, J. D., Zhang, A.-H., Rossi, R. J., Kolte, P. N., Griset, A. P., O’Neil, C., Altreuter, D. H., Browning, E., Johnston, L., Farokhzad, O. C., Langer, R., Scott, D. W., von Andrian, U. H., & Kishimoto, T. K.
- Affiliations
- Selecta Biosciences (United States) (US)
- Uniformed Services University of the Health Sciences (US)
- Brigham and Women's Hospital (US)
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139;
- Division of Immunology, Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115-6017; and
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2014-12-29
- Volume
- 112
- Issue
- 2
- Pages
- E156-65
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC4299193
- OpenAlex
- W2092747941
- Cited by
- 441
- References
- 48
- Citations by year
- 2026: 25 · 2025: 27 · 2024: 31 · 2023: 36 · 2022: 45 · 2021: 42 · 2020: 46 · 2019: 40 · 2018: 50 · 2017: 50 · 2016: 24 · 2015: 23
- FWCI
- 14.78
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
- Funders
- Juvenile Diabetes Research Foundation International (15-2011-265)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- polymeric nanoparticles, rapamycin, biodegradable nanoparticles, TLR agonists, regulatory T cells, B cell tolerance, T cell activation inhibition, experimental autoimmune encephalomyelitis, hemophilia A, factor VIII, hypersensitivity, autoimmune disease, allergy, antidrug antibodies, immunomodulation
- MeSH terms
- Polylactic Acid-Polyglycolic Acid Copolymer, Animals, Antigens, Disease Models, Animal, Encephalomyelitis, Autoimmune, Experimental, Factor VIII, Female, Hemocyanins, Hemophilia A, Humans, Hypersensitivity, Delayed, Immune Tolerance, Immunosuppression Therapy, Immunosuppressive Agents, Mice, Inbred BALB C, Oligodeoxyribonucleotides, Ovalbumin, Peptide Fragments, Peptides, Polyglycolic Acid, Proteins, Recombinant Proteins, CD4-Positive T-Lymphocytes, Lactic Acid, Sirolimus, Mice, Nanoparticles, Nanocapsules, Immunity, Humoral
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.